---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-046970"
form_type: "8-K"
ticker: "TELA"
cik: "0001561921"
company_name: "TELA Bio, Inc."
filed_at: "2024-04-15T23:59:59+00:00"
generated_at: "2026-06-03T22:54:38.345742+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# TELA Bio launches OviTex IHR for inguinal hernia repair in U.S.

## Summary
- OviTex IHR targets over 665,000 annual U.S. inguinal hernia procedures; three configurations available.
- Builds on OviTex portfolio with >45,000 implantations and 8 years clinical experience.
- Study on 259 patients using ReBAR technique showed low 1.2% recurrence rate at 1.5-year follow-up.
- Designed for laparoscopic and robotic-assisted repair; aims to address shortcomings of permanent synthetic mesh.

## SEC filing metadata
- accession: 0001104659-24-046970
- form_type: 8-K
- ticker: TELA
- cik: 0001561921
- company_name: TELA Bio, Inc.
- filed_at: 2024-04-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1561921/000110465924046970/0001104659-24-046970-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1561921/000110465924046970/tm2411582d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-046970
- JSON: https://secwatch.observer/filing/0001104659-24-046970.json
- Plain text: https://secwatch.observer/filing/0001104659-24-046970.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.